AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
BIL also holds an option to increase its equity stake by an additional 15%
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Subscribe To Our Newsletter & Stay Updated